Chronic Limb-Threatening Ischemia clinical trials at UCLA
3 in progress, 2 open to eligible people
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
open to eligible people ages 18-95
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Torrance 5403022, California 5332921 and other locations
SELUTION4BTK Trial
open to eligible people ages 18 years and up
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
Torrance 5403022, California 5332921 and other locations
PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Sorry, in progress, not accepting new patients
The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").
Torrance 5403022, California 5332921 and other locations
Our lead scientists for Chronic Limb-Threatening Ischemia research studies include Nikhil Kansal, MD Mark Archie.
Last updated: